Free Trial

Zhengye Biotechnology (ZYBT) Competitors

Zhengye Biotechnology logo
$2.44 -0.08 (-3.17%)
As of 10/24/2025 04:00 PM Eastern

ZYBT vs. CRVS, ARCT, ADCT, ORGO, INBX, MBX, ETON, ALMS, ATXS, and FULC

Should you be buying Zhengye Biotechnology stock or one of its competitors? The main competitors of Zhengye Biotechnology include Corvus Pharmaceuticals (CRVS), Arcturus Therapeutics (ARCT), ADC Therapeutics (ADCT), Organogenesis (ORGO), Inhibrx Biosciences (INBX), MBX Biosciences (MBX), Eton Pharmaceuticals (ETON), Alumis (ALMS), Astria Therapeutics (ATXS), and Fulcrum Therapeutics (FULC). These companies are all part of the "pharmaceutical products" industry.

Zhengye Biotechnology vs. Its Competitors

Corvus Pharmaceuticals (NASDAQ:CRVS) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

Zhengye Biotechnology has higher revenue and earnings than Corvus Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corvus PharmaceuticalsN/AN/A-$62.29M-$1.01-7.28
Zhengye Biotechnology$25.53M4.51$1.55MN/AN/A

In the previous week, Corvus Pharmaceuticals had 2 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 3 mentions for Corvus Pharmaceuticals and 1 mentions for Zhengye Biotechnology. Zhengye Biotechnology's average media sentiment score of 1.89 beat Corvus Pharmaceuticals' score of 0.63 indicating that Zhengye Biotechnology is being referred to more favorably in the news media.

Company Overall Sentiment
Corvus Pharmaceuticals Positive
Zhengye Biotechnology Very Positive

Corvus Pharmaceuticals presently has a consensus target price of $13.75, indicating a potential upside of 87.07%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Corvus Pharmaceuticals is more favorable than Zhengye Biotechnology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corvus Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Zhengye Biotechnology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Zhengye Biotechnology's return on equity of 0.00% beat Corvus Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Corvus PharmaceuticalsN/A -28.61% -18.05%
Zhengye Biotechnology N/A N/A N/A

46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 28.5% of Corvus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Corvus Pharmaceuticals beats Zhengye Biotechnology on 6 of the 11 factors compared between the two stocks.

Get Zhengye Biotechnology News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZYBT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZYBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZYBT vs. The Competition

MetricZhengye BiotechnologyMED IndustryMedical SectorNASDAQ Exchange
Market Cap$118.86M$3.43B$6.25B$10.65B
Dividend YieldN/A2.27%5.71%4.82%
P/E RatioN/A26.2230.7530.52
Price / Sales4.51471.45585.15186.19
Price / Cash24.4645.5737.0161.44
Price / Book2.3910.4012.056.61
Net Income$1.55M-$52.72M$3.33B$277.10M
7 Day Performance-8.27%2.10%1.88%2.54%
1 Month Performance-18.67%12.33%7.71%3.76%
1 Year PerformanceN/A14.14%56.33%33.04%

Zhengye Biotechnology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZYBT
Zhengye Biotechnology
N/A$2.44
-3.2%
N/AN/A$118.86M$25.53M0.00278Positive News
Gap Down
CRVS
Corvus Pharmaceuticals
2.0794 of 5 stars
$7.04
-1.0%
$13.75
+95.3%
-4.3%$529.79MN/A-6.9730Analyst Forecast
Gap Down
ARCT
Arcturus Therapeutics
3.4575 of 5 stars
$21.25
+9.6%
$50.57
+138.0%
-40.9%$526.54M$109.80M-9.53180Trending News
Analyst Downgrade
Analyst Revision
ADCT
ADC Therapeutics
2.4038 of 5 stars
$4.11
-11.0%
$7.75
+88.8%
+41.1%$518.62M$70.84M-2.61310News Coverage
Analyst Forecast
Gap Down
ORGO
Organogenesis
3.8837 of 5 stars
$4.00
+1.3%
$7.33
+83.3%
+48.4%$501.09M$482.04M-28.57950Gap Down
INBX
Inhibrx Biosciences
2.0488 of 5 stars
$34.81
+1.3%
N/A+272.7%$498.01M$200K-3.29166Trending News
Gap Up
MBX
MBX Biosciences
3.513 of 5 stars
$13.52
-6.8%
$42.80
+216.6%
N/A$487.11MN/A-2.98N/APositive News
Insider Trade
ETON
Eton Pharmaceuticals
2.485 of 5 stars
$18.77
+3.8%
$29.67
+58.1%
+125.4%$484.86M$39.01M-117.3120News Coverage
ALMS
Alumis
3.2728 of 5 stars
$4.63
+0.4%
$20.17
+335.6%
-62.3%$479.74MN/A0.00N/ANews Coverage
Positive News
Analyst Forecast
ATXS
Astria Therapeutics
1.866 of 5 stars
$11.61
+37.1%
$25.00
+115.3%
+6.5%$478MN/A-5.7830Analyst Forecast
High Trading Volume
FULC
Fulcrum Therapeutics
2.4804 of 5 stars
$8.69
-0.7%
$9.60
+10.5%
+184.6%$473.30M$80M-7.12100Analyst Forecast
Analyst Revision

Related Companies and Tools


This page (NASDAQ:ZYBT) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners